Come up with a name for your new list and we'll add to it:
Keapstone Therapeutics raised a round of funding on September 26, 2018. Investors include
Parkinson's Disease Society of the United Kingdom.
Keapstone Therapeutics is developing a series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson's and amyotrophic lateral sclerosis (ALS).…